No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:22:17.550Z. Latest historical point 2026-05-13. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T22:22:17.550Z. Latest historical point 2023-05-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:22:17.550Z. Latest historical point 2023-05-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Century Therapeutics, Inc. (IPSC) stock was $1.32 as of Oct 6, 2026, 4:00 PM EDT, down 10.81% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +186.9% · 3-year avg -4.5%/yr · 5-year avg -42.0%/yr
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies.
Biotechnology · Philadelphia, PA
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.12
Revenue Est.
$1.63M
Last Quarter Results
EPS
$-0.11
vs Estimate
$-0.12
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IPSC | $239.02M | $1.32 | -10.81% | +186.88% | -42.05% | N/A | N/A |
| 2HITI | $239.01M | $2.72 | -0.37% | -23.43% | -14.29% | N/A | vs IPSC |
| 3IVVD | $237.57M | $0.81 | -3.91% | -27.54% | -51.69% | N/A | vs IPSC |
| 4BIOA | $236.82M | $6.29 | -1.10% | +13.30% | N/A | N/A | vs IPSC |
| 5QSI | $241.34M | $1.22 | -4.69% | -25.48% | -31.06% | N/A | vs IPSC |
| 6QTTB | $241.39M | $8.11 | -3.11% | +301.66% | -41.51% | N/A | vs IPSC |
forward FY estimate
N/A
$0.00
vs Estimate
$2.17M
Consensus Rating
Based on 4 analysts
Average Price Target
$4.75
+259.8% upside
Low
$2.00
Current
$1.32
High
$8.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.12 | $-0.12 | $-0.12 | 2 |
| Quarter ending Dec 2026 | $-0.13 | $-0.13 | $-0.12 | 2 |
| Quarter ending Mar 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
| Quarter ending Jun 2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.52 | $-0.52 | $-0.51 | 3 |
| FY 2027 | $-0.48 | $-0.45 | $-0.41 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.63M | $1.63M | $1.63M | 2 |
| Quarter ending Dec 2026 | $1.20M | $1.20M | $1.20M | 2 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.72M | $4.72M | $4.72M | 3 |
| FY 2027 | $3.73M | $3.73M | $3.73M | 4 |
